Drugs / CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07152223 | Aug 2025 → Mar 2026 | connective tissue disorder | Guangzhou Bio-gene Technology Co., Ltd | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07152223 ↗ |
| Modality | Cell therapy | “preliminary efficacy of CD19-BCMA CAR-T cells in subjects diagnosed with connective tissue diseases.” NCT07152223 ↗ |
| Route | Intravenous | “administered intravenously.” NCT07152223 ↗ |